Drug Designing: Open Access is a peer-reviewed multidisciplinary scholarly journal aims to publish reliable source of scientific information on Drug Research and applied fields. The Journal aims to provide platform for the researchers, expertise in physics sciences disciplines, for disseminating experimental and theoretical reports reporting the progress of Physics Research and its advancing significant interdisciplinary applications researchers, expertise in physics sciences disciplines, for disseminating experimental and theoretical reports reporting the progress of Physics Research and its advancing significant interdisciplinary applications and  journal aims to publish reliable source of scientific information on Drug Research and applied fields.

Artificial intelligence (AI) uses personified knowledge and learns from the solutions it produces to address not only specific but also complex problems. Remarkable improvements in computational power coupled with advancements in AI technology could be utilised to revolutionise the drug development process. At present, the pharmaceutical industry is facing challenges in sustaining their drug development programmes because of increased R&D costs and reduced efficiency. In this review, we discuss the major causes of attrition rates in new drug approvals, the possible ways that AI can improve the efficiency of the drug development process and collaboration of pharmaceutical industry giants with AI-powered drug discovery firms.

The manuscripts qualified from quality check will be allowed for review by the subject matter expert referees, under the guidance of the Handling Editor or Editor-in-Chief of the Journal. The Journal invites potential authors to bring out novel researches in the field of Pharma Sciences through scientific publications.

Submit manuscript at www.longdom.org/submissions/drug-designing-open-access.html 

With Regards,

Sherry Peterson
Drug Designing: Open Access
Editorial Manager
Email: drugdesign@longdom.org
Whats App:+1-947-333-4405.